Zuzanna Kanduła

7PUBLICATIONS
41CO-AUTHORS
Haematological tumoursMedical infection agents (incl. prions)Medical mycologyMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 17, 2025
Coexisting Myeloproliferative and Lymphoid Neoplasms: A European Multicenter Retrospective Study.

Dolly Viviana Fiallo-Suárez, Ruth Stuckey, Cristina Bilbao-Sieyro

|Jul 28, 2023
High molecular risk variants, severe thrombocytopenia and large unstained cells count affect the outcome in primary myelofibrosis.

Zuzanna Kanduła, Michał Janowski, Barbara Więckowska

|Jan 06, 2023
HRAS mutation positive multiple myeloma in the type 2 CALR mutation positive essential thrombocythemia: A case report.

Krzysztof Lewandowski, Agata Kopydłowska, Zuzanna Kanduła

|Oct 20, 2022
Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.

Krzysztof Lewandowski, Zuzanna Kanduła, Michał Gniot

|Oct 15, 2022
JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.

Zuzanna Kanduła, Michał Janowski, Barbara Więckowska

|Apr 18, 2022
Rapid progression of myelofibrosis in polycythemia vera patient carrying SRSF2 c.284C>A p.(Pro95His) and unique ASXL1 splice site c.1720-2A>G variant.

Zuzanna Kanduła, Renata Kroll-Balcerzak, Krzysztof Lewandowski

Pageof 2